Successful Treatment of Refractory Takayasu Arteritis with Tocilizumab—A Case Report

Abstract Takayasu arteritis (TA) is an idiopathic inflammatory vasculitis mostly affecting young females in the second or third decades of life. Corticosteroids and conventional immunosuppressants remain the mainstay of treatment for TA, but refractory cases are dealt with biological agents. The high cost and longer duration of therapy are issues of concern. Here, we report a case of a patient with refractory TA who underwent successful treatment with tocilizumab, a humanized monoclonal antibody against interleukin-6 receptor